Listen to the call. The CEO explains why. The FDA changed their minds. The FDA changed their minds after they saw the submitted results/data. The FDA decided that for the data to be clinically relevant Cytodyn would have to have 50 patients total for analysis. Plain and simple the FDA changed their minds along the way.